Ochre Bio: Raises $9.6M in Seed Financing
- Ochre Bio, an Oxford, England, UK-based biotech company developing RNA medicines for chronic liver diseases, closed a $9.6M seed financing
- The round was led by Khosla Ventures, with participation from Backed VC, Apollo Health Ventures, Selvedge, Hoxton and Hermes-Epitek
- The company intends to use the funds to advance the development of its RNA therapies and expand their deep phenotyping platform to identify and validate new liver targets
- The company is a biotechnology company developing RNA medicines for chronic liver diseases
- The company has built a deep phenotyping platform to identify novel liver targets, validated directly in discarded human livers kept alive on machines
- In addition to deep phenotyping of human livers, the company is able to test therapeutics in explanted livers being maintained extracorporeally
